Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST)

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST)

BackgroundBetahistine was registered in Europe in the 1970s and approved in more than 80 countries as a first-line treatment for Menière's disease. It has been administered to more than 150 million patients. However, according to a Cochrane systematic review of betahistine and recent meta-analy...

Full description

Bibliographic Details
Main Authors: Michael Strupp, Grant C. Churchill, Ivonne Naumann, Ulrich Mansmann, Amani Al Tawil, Anastasia Golentsova, Nicolina Goldschagg
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Neurology
Subjects:
betahistine
selegiline
MAO-B inhibitor
phase 1 trial
Menière
vertigo
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1271640/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1271640/full

Similar Items